论文部分内容阅读
目的:探讨survivin在非小细胞肺癌组织(non small cell lung cancer,NSCLC)中的表达,及其与bc 1 2、p63蛋白表达的相关性。方法:应用二步法免疫组织化法,检测survivin、bc 1-2、p63蛋白在60例NSCLC组织和20例正常肺组织中的表达。结果:肺癌组织中的survivin蛋白阳性率(56．67%)明显高于正常肺组织15%),有显著性差异;(p＜0．05)Ⅲ期surviving蛋白阳性表达率72．73%(16/22)明显高于Ⅰ+Ⅱ期survivin47．37%(18/38)。有显著差异;(p＜0．05)survivin蛋白表达与患者年龄、病理类型、组织分化程度,淋巴结转移情况无关(P＞0．05)NSCLC组织bc 1-2蛋白表达阳性、阴性组中,survivin蛋白阳性表达率分别为66．67% (18/27)和48．48%(16/33),两者比较,差异有显著性(P＜0．05);p63蛋白表达阳性、阴性组中,survivin蛋白阳性表达率分别为53．33%(16/30)和60%(18/30),两者比较,差异有显著性(P＜0．05)survivin,蛋白与bc 1-2蛋白的表达呈正相关。survivin蛋白与p63蛋白的表达呈正相关。结论:survivin在NSCLC组织中表达上调,通过抑制细胞凋亡,在NSCLC的发生和发展中起到重要作用。survivin,bc 1-2与p63它们分别在肺癌发生发展过程中不同途径上抑制肺癌细胞的凋亡,对肺癌早期诊断有一定的意义。对3种蛋白进行联合检测,更有利于肺癌的早期诊断和判断肺癌的分化程度、临床分期、淋巴结是否转移及病人的预后。survivin与bc1-2及survivin与p63可能起协同作用,并可能会成为NSCLC基因治疗的新靶点。
Objective: To investigate the expression of survivin in non small cell lung cancer (NSCLC) and its relationship with bc 1 2, p63 protein expression. Methods: The expression of survivin, bc 1-2 and p63 protein in 60 NSCLC tissues and 20 normal lung tissues were detected by two-step immunohistochemistry. Results: The positive rate of survivin protein in lung cancer tissues was significantly higher than that in normal lung tissues (56.67% vs 15%, P <0.05). The positive rate of survivin protein in stage Ⅲ was 72.73% 16/22) was significantly higher than that of Ⅰ + Ⅱ survivin47.37% (18/38). (P <0.05). The expression of survivin protein had no correlation with the age, pathological type, histological differentiation and lymph node metastasis (P> 0.05) The positive rate of survivin protein expression was 66.67% (18/27) and 48.48% (16/33) respectively, there was significant difference between the two groups (P <0.05) , The positive rates of survivin protein expression were 53.33% (16/30) and 60% (18/30) respectively, there was a significant difference between the two groups (P <0.05) Protein expression was positively correlated. Survivin protein and p63 protein expression was positively correlated. Conclusion: Survivin is upregulated in NSCLC tissues and plays an important role in the development and progression of NSCLC by inhibiting apoptosis. Survivin, bc 1-2 and p63, respectively, inhibit the apoptosis of lung cancer cells in different ways during the development and progression of lung cancer and have certain significance for the early diagnosis of lung cancer. Joint detection of three proteins is more conducive to the early diagnosis of lung cancer and to determine the degree of differentiation of lung cancer, clinical stage, lymph node metastasis and prognosis of patients. Survivin, bcl-2, survivin and p63 may play synergistic roles in the gene therapy of NSCLC.